Company Information

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE5376.30-64.25 (-1.18 %)
PREV CLOSE ( ) 5440.55
OPEN PRICE ( ) 5440.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1611
TODAY'S LOW / HIGH ( )5342.75 5440.55
52 WK LOW / HIGH ( )4409.9 6440
NSE5372.55-62.7 (-1.15 %)
PREV CLOSE( ) 5435.25
OPEN PRICE ( ) 5435.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 5372.55 (49)
VOLUME 70477
TODAY'S LOW / HIGH( ) 5341.55 5447.00
52 WK LOW / HIGH ( )4407.05 6439.9
ChairmanBasudeo N Singh
Managing DirectorSandeep Singh
Company SecretaryManish Narang
Executive DirectorMritunjay Kumar Singh
Madhurima Singh
Sarvesh Singh
Srinivas Singh
Independent DirectorRajeev Kher
Non Executive Independent DirectorArun Kumar Purwar
Narendra Kumar Aneja
Sangeeta Singh
Sudha Ravi
Sujjain Talwar
Incorporation Year : 08-08 1973

Registered Office :

Address : Alkem House,Senapati Bapat Marg,Lower Parel (West) Mumbai,
Maharashtra-400013 .

Phone : 022 3982 9999

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.